NCT05690880Active, not recruiting
ForeseeHome NRich Registry
Source: ClinicalTrials.gov · Last updated 15 Feb 2023
Brief summary (registry, in English)
This registry will compare functional and structural data of progression of Intermediate AMD (iAMD) and conversion to neovascular AMD (NV-AMD) while monitored at home with the ForeseeHome Monitoring System (FSH) and during routine care with Spectral Domain Optical Coherence Tomography (SD-OCT) and to validate the predictive value of a non-NV-AMD FSH alerts.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 20000 (estimated)
- First submitted
- 10 Jan 2023
- Start date
- 15 Dec 2022
- Primary completion date
- 15 Dec 2027
- Lead sponsor
- Notal Vision Inc.
- Diseases
- Macular degeneration
- NCT number
- NCT05690880
What you commit to
- Study type: Observational
- Planned participants: 20000
- From 15 Dec 2022 to the primary completion date, 15 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients that are unable to establish a baseline
Who the study is looking for
- The participants include those actively monitoring on the FSH program which requires diagnosis of intermediate AMD and visual acuity of 20/60 or better that establish a valid baseline in at least one eye.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| NJ Retina Coordinator of this site? Confirm its status | Toms River | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.